Advertisement

Review of the Emerging Treatment of Clostridium difficile Infection with Fecal Microbiota Transplantation and Insights into Future Challenges

  • Zain Kassam
    Affiliations
    Department of Biological Engineering, Massachusetts Institute of Technology, 777 Massachusetts Avenue, 56-651, Cambridge, MA 02139, USA
    Search for articles by this author
  • Christine H. Lee
    Affiliations
    Division of Infectious Diseases, Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada

    Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8, Canada

    Hamilton Regional Laboratory Medicine Program, 50 Charlton Avenue, Hamilton, Ontario L8N 4A6, Canada
    Search for articles by this author
  • Richard H. Hunt
    Correspondence
    Corresponding author. Division of Gastroenterology, McMaster University Health Science Centre, Room 3V3, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada.
    Affiliations
    Division of Gastroenterology, Department of Medicine, McMaster University Health Science Centre, McMaster University, Room 3V3, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada

    Farncombe Family Digestive Health Research Institute, Health Sciences Centre, Rm 3N4, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada
    Search for articles by this author
Published:September 25, 2014DOI:https://doi.org/10.1016/j.cll.2014.08.007

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Magill S.S.
        • Edwards J.R.
        • Bamberg W.
        • et al.
        Multistate point-prevalence survey of health care-associated infections.
        N Engl J Med. 2014; 370: 1198-1208
        • Collins C.
        • Ayturk M.
        • Flahive J.
        Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries.
        J Am Coll Surg. 2014; 218: 1141-1148
        • Zilberberg M.
        • Shorr A.
        • Kollef M.
        Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005.
        Emerg Infect Dis. 2008; 14: 929-931
        • Gravel D.
        • Miller M.
        • Simor A.
        • et al.
        Health care‘ associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study.
        Clin Infect Dis. 2009; 48: 568-576https://doi.org/10.1086/596703
        • Bauer M.P.
        • Notermans D.W.
        • van Benthem B.H.
        • et al.
        Clostridium difficile infection in Europe: a hospital-based survey.
        Lancet. 2011; 377: 63-73https://doi.org/10.1016/S0140-6736(10)61266-4
        • Simango C.
        • Uladi S.
        Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe.
        Trans R Soc Trop Med Hyg. 2014; 108: 354-357https://doi.org/10.1093/trstmh/tru042
        • Wiegand P.N.
        • Nathwani D.
        • Wilcox M.H.
        • et al.
        Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of health care-facility-acquired infection.
        J Hosp Infect. 2012; 81: 1-14https://doi.org/10.1016/j.jhin.2012.02.004
        • McGlone S.
        • Bailey R.
        • Zimmer S.
        The economic burden of Clostridium difficile.
        Clin Microbiol Infect. 2012; 18: 282-289https://doi.org/10.1111/j.1469-0691.2011.03571.x
        • Dubberke E.
        • Olsen M.
        Burden of Clostridium difficile on the health care system.
        Clin Infect Dis. 2012; 55: S88-S92https://doi.org/10.1093/cid/cis335
        • Vonberg R.
        • Reichardt C.
        • Behnke M.
        Cost of nosocomial Clostridium difficile-associated diarrhoea.
        J Hosp Infect. 2008; 70: 15-20
        • Kelly C.P.
        • Lamont J.T.
        Clostridium difficile — more difficult than ever.
        N Engl J Med. 2008; 359: 1932-1940
        • Lynch T.
        • Chong P.
        • Zhang J.
        • et al.
        Characterization of a stable, metronidazole-resistant clostridium difficile clinical isolate.
        PLoS One. 2013; 8: e53757https://doi.org/10.1371/journal.pone.0053757
        • Baines S.D.
        • O’Connor R.
        • Freeman J.
        • et al.
        Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
        J Antimicrob Chemother. 2008; 62: 1046-1052https://doi.org/10.1093/jac/dkn313
        • Peláez T.
        • Alcalá L.
        • Alonso R.
        • et al.
        Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
        Antimicrob Agents Chemother. 2002; 46: 1647-1650https://doi.org/10.1128/AAC.46.6.1647
        • O’Horo J.C.
        • Jindai K.
        • Kunzer B.
        • et al.
        Treatment of recurrent Clostridium difficile infection: a systematic review.
        Infection. 2014; 42: 43-59https://doi.org/10.1007/s15010-013-0496-x
        • Petrella L.A.
        • Sambol S.P.
        • Cheknis A.
        • et al.
        Decreased cure and increased recurrence rates for clostridium difficile infection caused by the epidemic C. difficile BI strain.
        Clin Infect Dis. 2012; 55: 351-357https://doi.org/10.1093/cid/cis430
        • Barbut F.
        • Richard A.
        • Hamadi K.
        Epidemiology of recurrences or reinfections of Clostridium difficile epidemiology of recurrences or reinfections of Clostridium difficile -associated diarrhea.
        J Clin Microbiol. 2000; 38: 2386-2388
        • Louie T.J.
        • Miller M.A.
        • Mullane K.M.
        • et al.
        Fidaxomicin versus vancomycin for Clostridium difficile infection.
        N Engl J Med. 2011; 364: 422-431
        • Pépin J.
        • Saheb N.
        • Coulombe M.A.
        • et al.
        Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
        Clin Infect Dis. 2005; 41: 1254-1260
        • McFarland L.V.
        • Elmer G.W.
        • Surawicz C.M.
        Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
        Am J Gastroenterol. 2002; 97: 1769-1775
        • Song Y.
        • Garg S.
        • Girotra M.
        • et al.
        Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.
        PLoS One. 2013; 8: e81330https://doi.org/10.1371/journal.pone.0081330
        • Chang J.Y.
        • Antonopoulos D.A.
        • Kalra A.
        • et al.
        Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea.
        J Infect Dis. 2008; 197: 435-438https://doi.org/10.1086/525047
        • Khoruts A.
        • Dicksved J.
        • Jansson J.K.
        • et al.
        Khoruts 2010.
        J Clin Gastroenterol. 2010; 44: 354-360
        • Zhang F.
        • Luo W.
        • Shi Y.
        • et al.
        Should we standardize the 1,700-year-old fecal microbiota transplantation?.
        Am J Gastroenterol. 2012; 107 ([author reply: 1755–6]): 1755https://doi.org/10.1038/ajg.2012.251
        • Kassam Z.
        • Lee C.H.
        • Yuan Y.
        • et al.
        Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.
        Am J Gastroenterol. 2013; 108: 500-508https://doi.org/10.1038/ajg.2013.59
        • Guo B.
        • Harstall C.
        • Louie T.
        • et al.
        Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease.
        Aliment Pharmacol Ther. 2012; 35: 865-875https://doi.org/10.1111/j.1365-2036.2012.05033.x
        • Gough E.
        • Shaikh H.
        • Manges A.R.
        Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection.
        Clin Infect Dis. 2011; 53: 994-1002https://doi.org/10.1093/cid/cir632
        • Sha S.
        • Liang J.
        • Chen M.
        • et al.
        Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children.
        Aliment Pharmacol Ther. 2014; 39: 1003-1032https://doi.org/10.1111/apt.12699
        • Smith M.B.
        • Kelly C.
        • Alm E.J.
        How to regulate faecal transplants.
        Nature. 2014; 506: 290-291
        • Moayyedi P.
        • Marshall J.K.
        • Yuan Y.
        • et al.
        Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy.
        Can J Gastroenterol. 2014; 28: 1-3
        • Kassam Z.
        • Murray T.S.
        Navigating the pediatric microbiome: emerging evidence and clinical implications.
        Curr Pediatr Rep. 2014; 2: 93-101https://doi.org/10.1007/s40124-014-0040-1
        • Van Nood E.
        • Vrieze A.
        • Nieuwdorp M.
        • et al.
        Duodenal infusion of donor feces for recurrent Clostridium difficile.
        N Engl J Med. 2013; 368: 407-415https://doi.org/10.1056/NEJMoa1205037
        • Youngster I.
        • Sauk J.
        • Pindar C.
        • et al.
        Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study.
        Clin Infect Dis. 2014; 58: 1-8https://doi.org/10.1093/cid/ciu135
        • Konijeti G.G.
        • Sauk J.
        • Shrime M.G.
        • et al.
        Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
        Clin Infect Dis. 2014; 58: 1-8https://doi.org/10.1093/cid/ciu128
        • Kassam Z.
        • Hundal R.
        • Marshall J.
        • et al.
        Fecal transplant via retention enema for refractory or recurrent clostridium difficile infection.
        Arch Intern Med. 2012; 172: 2012-2014
        • Mattila E.
        • Uusitalo-Seppälä R.
        • Wuorela M.
        • et al.
        Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.
        Gastroenterology. 2012; 142: 490-496https://doi.org/10.1053/j.gastro.2011.11.037
        • Kelly C.R.
        • Ihunnah C.
        • Fischer M.
        • et al.
        Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.
        Am J Gastroenterol. 2014; 109: 1065-1071https://doi.org/10.1038/ajg.2014.133
        • Cohen S.H.
        • Gerding D.N.
        • Johnson S.
        • et al.
        Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for health care epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).
        Infect Control Hosp Epidemiol. 2010; 31: 431-455https://doi.org/10.1086/651706
        • Surawicz C.M.
        • Brandt L.J.
        • Binion D.G.
        • et al.
        Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.
        Am J Gastroenterol. 2013; 108 ([quiz: 499]): 478-498https://doi.org/10.1038/ajg.2013.4
        • Debast S.B.
        • Bauer M.P.
        • Kuijper E.J.
        Comm. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.
        Clin Microbiol Infect. 2014; 20: 1-26
        • Bakken J.S.
        • Borody T.
        • Brandt L.J.
        • et al.
        Treating Clostridium difficile infection with fecal microbiota transplantation.
        Clin Gastroenterol Hepatol. 2011; 9: 1044-1049https://doi.org/10.1016/j.cgh.2011.08.014
        • Allen-Vercoe E.
        • Reid G.
        • Viner N.
        • et al.
        A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics.
        Can J Gastroenterol. 2012; 26: 457-462
        • Lee C.H.
        • Belanger J.E.
        • Kassam Z.
        • et al.
        The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema.
        Eur J Clin Microbiol Infect Dis. 2014; 33: 1425-1428https://doi.org/10.1007/s10096-014-2088-9
        • Collins S.M.
        • Kassam Z.
        • Bercik P.
        The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications.
        Curr Opin Microbiol. 2013; 16: 240-245
        • Schwartz M.
        • Gluck M.
        • Koon S.
        Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts.
        Am J Gastroenterol. 2013; 108: 1367https://doi.org/10.1038/ajg.2013.164
        • Brandt L.J.
        • Aroniadis O.C.
        • Mellow M.
        • et al.
        Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
        Am J Gastroenterol. 2012; 107: 1079-1087https://doi.org/10.1038/ajg.2012.60
        • Kassam Z.
        • Lee C.H.
        • Yuan Y.
        • et al.
        Navigating long-term safety in fecal microbiota transplantation.
        Am J Gastroenterol. 2013; 108: 1538https://doi.org/10.1038/ajg.2013.214
        • Aas J.
        • Gessert C.E.
        • Bakken J.S.
        Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube.
        Clin Infect Dis. 2003; 36: 580-585https://doi.org/10.1086/367657
        • Silverman M.S.
        • Davis I.
        • Pillai D.R.
        Success of self-administered home fecal transplantation for chronic Clostridium difficile infection.
        Clin Gastroenterol Hepatol. 2010; 8: 471-473https://doi.org/10.1016/j.cgh.2010.01.007
        • Yoon S.S.
        • Brandt L.J.
        Treatment of refractory/recurrent C. difficile- associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients.
        J Clin Gastroenterol. 2010; 44: 562-566
        • Kelly C.R.
        • de Leon L.
        • Jasutkar N.
        Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.
        J Clin Gastroenterol. 2012; 46: 145-149https://doi.org/10.1097/MCG.0b013e318234570b
        • Borody T.J.
        • Warren E.F.
        • Leis S.M.
        • et al.
        Bacteriotherapy using fecal flora.
        J Clin Gastroenterol. 2004; 38: 475-483https://doi.org/10.1097/01.mcg.0000128988.13808.dc
        • Lund-Tønnesen S.
        • Berstad A.
        • Schreiner A.
        • et al.
        Clostridium difficile-associated diarrhea treated with homologous feces.
        Tidsskr Nor Laegeforen. 1998; 118: 1027-1030
        • Hamilton M.J.
        • Weingarden A.R.
        • Sadowsky M.J.
        • et al.
        Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.
        Am J Gastroenterol. 2012; 107: 761-767https://doi.org/10.1038/ajg.2011.482
        • Garborg K.
        • Waagsbø B.
        • Stallemo A.
        • et al.
        Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea.
        Scand J Infect Dis. 2010; 42: 857-861https://doi.org/10.3109/00365548.2010.499541
        • Schwan A.
        • Sjolin S.
        • Trottestam U.
        • et al.
        Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces.
        Lancet. 1983; 2: 845
        • Petrof E.O.
        • Gloor G.B.
        • Vanner S.J.
        • et al.
        Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut.
        Microbiome. 2013; 1: 3https://doi.org/10.1186/2049-2618-1-3
      1. Louie T, Cannon K, O’Grady H, et al. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). Abstract presented at The ID Week Conference. 2014.

      2. Kelly C. Fecal transplant for relapsing C. Difficile infection. 2014. U.S. National Institutes of Health Trial Register. NCT Number 01703494. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01703494?term=fecal+transplant & rank=4. Accessed July 14, 2014.

      3. Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection in adults and children using a frozen encapsulated inoculum. 2014. U.S. National Institutes of Health Trial Register. NCT Number NCT01914731. Available at: http://clinicaltrials.gov/ct2/show/NCT01914731?term=fecal&rank=17. Accessed July 14, 2014.

      4. Lee C. Multi-centre trial of fresh vs frozen-and-thawed HBT (fecal transplant) for recurrent CDI. 2014. Available at: U.S. National Institutes of Health Trial Register. NCT Number 01398969. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01398969?term=fecal+transplant & rank=2. Accessed July 14, 2014.

      5. Hota S. Oral vancomycin followed by fecal transplant vs. tapering oral vancomycin. 2014. U.S. National Institutes of Health Trial Register. NCT Number 01226992. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01226992?term=feca l+transplant & rank=1. Accessed July 12, 2014.

      6. Gisser J. Fecal transplant for pediatric patients who have recurrent C-diff infection (FMT). 2014. Available at: U.S. National Institutes of Health Trial Register. NCT Number NCT02134392. Available at: http://clinicaltrials.gov/ct2/show/NCT02134392?term=gisser&rank=1. Accessed July 12, 2014.

        • Lawley T.D.
        • Clare S.
        • Walker A.W.
        • et al.
        Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice.
        PLoS Pathog. 2012; 8: e1002995https://doi.org/10.1371/journal.ppat.1002995
        • Merenstein D.
        • El-Nachef N.
        • Lynch S.
        Fecal microbial therapy - promises and pitfalls.
        J Pediatr Gastroenterol Nutr. 2014; https://doi.org/10.1097/MPG.000000000000415
      7. Smith M, Kassam Z, Edelstein C, et al. OpenBiome. 2014. Available at: http://www.openbiome.org/. Accessed July, 2014.

      8. FDA. Vaccine and Related Biological Product Guidances - draft guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. 2014. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm387023.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed September 18, 2014.